U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5O7.3Ag
Molecular Weight 512.7043
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SILVER CITRATE

SMILES

[Ag+].[Ag+].[Ag+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=QUTYHQJYVDNJJA-UHFFFAOYSA-K
InChI=1S/C6H8O7.3Ag/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3

HIDE SMILES / InChI

Molecular Formula Ag
Molecular Weight 107.8682
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H5O7
Molecular Weight 189.0997
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/monograph/silver-nitrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18245232

Silver iodide is an inorganic compound with the formula AgI. It is used as a photosensitive agent in photography, as a local antiseptic, as a chemical intermediate, and in cloud seeding for rain-making. The major hazards encountered in the use and handling of silver iodide stem from its toxicologic properties. Effects from exposure may include skin rashes, conjunctivitis, argyria (a permanent ashen-gray discoloration of skin, conjunctiva, and internal organs), headache, fever, hypersensitivity, laryngitis, and bronchitis.

Originator

Sources: Vestsi Akademii Navuk BSSR, Seryya Khimichnykh Navuk, Issue 2, Pages 69-73, Journal, 1990https://www.ncbi.nlm.nih.gov/pubmed/20429870
Curator's Comment: The medical uses of silver date back to at least the time of Hippocrates

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Advantage Arrest Silver Diamine Fluoride

Approved Use

Unknown
Primary
Advantage Arrest Silver Diamine Fluoride

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
Primary
Colloidal silver iodide

Approved Use

Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Primary
Colloidal silver iodide

Approved Use

Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Palliative
Unknown

Approved Use

Antiseptic Wound Cauterization
Primary
Unknown

Approved Use

Prophylaxis of gonococcal ophthalmia neonatorum. AAP recommends use of topical silver nitrate, povidone-iodine, or possibly erythromycin for prophylaxis of nongonococcal nonchlamydial conjunctivitis in neonates, ideally administered shortly after birth.
PubMed

PubMed

TitleDatePubMed
Directional growth of Ag nanorod from polymeric silver cyanide: A potential substrate for concentration dependent SERS signal enhancement leading to melamine detection.
2017-08-05
The antifungal effects and mechanical properties of silver bromide/cationic polymer nano-composite-modified Poly-methyl methacrylate-based dental resin.
2017-05-08
UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent.
2016-01
An alternate technique of care using silver fluoride followed by stannous fluoride in the management of root caries in aged care.
2015-12-22
A novel silver iodide metalo-drug: experimental and computational modelling assessment of its interaction with intracellular DNA, lipoxygenase and glutathione.
2014-04-22
Development of silica-coated silver iodide nanoparticles and their biodistribution.
2012-12
Cleaning and decontamination efficacy of wiping cloths and silver dihydrogen citrate on food contact surfaces.
2012-07
Topical antimicrobials for burn wound infections.
2010-06
Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli.
2008-04
Photocatalytic degradation of pathogenic bacteria with AgI/TiO2 under visible light irradiation.
2007-04-24
Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses.
2005-03
New disinfection and sterilization methods.
2001-04-11
A chemically intelligent antimicrobial coating for urologic devices.
2000-02
Lack of genotoxicity of silver iodide in the SCE assay in vitro, in vivo, and in the Ames/microsome test.
1998
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Toxicity data
Topical as a 1:80 dilution (30 ppm ionic silver).
Route of Administration: Topical
10 mkl volume of undiluted human norovirus 20% faecal suspension was mixed with 90 mkl of SDC (Silver Dihydrogen Citrate) for various contact times (15, 30, 60, 120, 300, 600 and 1800 s). At each sampling time point, 20 mkl of this solution was added to 180 mkl of 10% solution of Dey/Engley (D/E) neutralizing broth (Thermo Fisher Scientific, Waltham, MA). Samples were aliquoted and frozen at -80°C prior to nucleic acid extraction.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:45:01 GMT 2025
Edited
by admin
on Mon Mar 31 18:45:01 GMT 2025
Record UNII
CKA421A1J7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, SILVER(1+) SALT (1:3)
Preferred Name English
SILVER CITRATE
INCI   MI   WHO-DD  
INCI  
Official Name English
2-HYDROXY-1,2,3-PROPANETRICARBOXYLIC ACID SILVER SALT
Common Name English
Silver citrate [WHO-DD]
Common Name English
TRISILVER CITRATE
Systematic Name English
SILVER CITRATE [MI]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 310.548
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
204-786-8
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY
RXCUI
1306066
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY RxNorm
DAILYMED
CKA421A1J7
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY
EPA CompTox
DTXSID70889420
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY
PUBCHEM
101599
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY
FDA UNII
CKA421A1J7
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY
CAS
126-45-4
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY
DRUG BANK
DB11233
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY
MERCK INDEX
m9920
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY Merck Index
SMS_ID
100000182572
Created by admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY